Is Angiotensin (1-7) FDA approved?

Angiotensin (1-7) is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is Angiotensin (1-7) administered in research settings?

In research settings, Angiotensin (1-7) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Endoluten administered in research settings?

In research settings, Endoluten is typically administered via the oral or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Angiotensin (1-7) vs Endoluten

Peptide Comparison

Angiotensin (1-7) vs Endoluten

Q: What is the difference between Angiotensin (1-7) and Endoluten?

Angiotensin (1-7): Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Endoluten: Pineal-targeted peptide complex that modulates melatonin synthesis pathways and circadian gene expression. May help restore age-related decline in pineal activity and improve circadian rhythm regulation.

Both are Longevity & Cellular peptides.

Angiotensin (1-7)

Ang-(1-7)

LongevityInvestigationalResearch Only

Half-life: ~9–10 sec (rat)

No providers listed yet

Full Angiotensin (1-7) profile →

Endoluten

pineal peptide bioregulator

LongevityResearch Only

1 providers listed

Full Endoluten profile →

Bottom line

Angiotensin (1-7) carries stronger published evidence (RCT, 15 key studies) than Endoluten (Review, 1); both are research compounds.

Quick Verdict

Angiotensin (1-7)

Evidence

Clinical

Half-life

~9–10 sec (rat)

Endoluten

Evidence

Review-level

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Angiotensin (1-7)
Further along in FDA review	Angiotensin (1-7)
Oral administration option	Endoluten
More provider options (0 vs 1)	Endoluten

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Angiotensin (1-7)

Endoluten

Mechanism Family

Longevity & Cellular

Half-life

~9–10 sec (rat)

—

FDA Status

investigational

unknown

Admin Routes

subcutaneous, intravenous

oral, subcutaneous

Availability

Research Only

Providers

None listed

1 listed

Research Evidence

Angiotensin (1-7)

ClinicalRCT · 15 key studies · most recent 2026

Endoluten

Review-levelReview · 1 key study · dated evidence base — most recent 2002

Research Citations

Angiotensin (1-7)

Cohort2026 · Metabolites

The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.

Cohort2026 · Res Sq

Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…

Cohort2026 · Hypertension

Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.

Cohort2026 · Front Pharmacol

Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the re…

+11 more

Endoluten

Review2002 · Neuroendocrinology Letters

Peptides and ageing

About Angiotensin (1-7)

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Research Areas

cardiovascular protectionanti-fibroticvasodilationinsulin sensitivitykidney protection

About Endoluten

Pineal-targeted peptide complex that modulates melatonin synthesis pathways and circadian gene expression. May help restore age-related decline in pineal activity and improve circadian rhythm regulation.

Research Areas

circadian rhythm supportmelatonin pathwaysleep qualitylongevityanti-aging

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Angiotensin (1-7)

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Endoluten

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Find Providers

Where to source these peptides

Providers offering

Angiotensin (1-7)

Browse directory →

Providers offering

Endoluten

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.